Dr. Daniel Lévesque

Professor, Université de Montréal

Dr. Lévesque joined the Faculty of Medicine of the Laval University (Quebec city) as an adjunct professor in 1995. In 2006, he transferred his research and academic activities at the Faculty of Pharmacy of the University of Montreal, where he obtained a full professor position in 2009. His research mainly focuses on the role of transcription factors of the nuclear receptor family into the mechanism of action of drugs targeting dopamine neurotransmission, such as antiparkinsonians, antipsychotics and drugs of abuse. In particular, his team has demonstrated the role of transcriptional complexes composed of Nurs (Nur77, Nurr1) and retinoid X receptor (RXR) into L-Dopa-induced dyskinesia, as well as tardive dyskinesia induced after prolonged exposition to antipsychotic drugs, in various animal models (rat, mouse, monkey). As an independent investigator, he obtained numerous salary awards and research grants from national and international funding agencies or foundations, including the Fonds de la Recherche en Santé du Québec (FRSQ), the Canadian Institutes of Health Research (CIHR), Canadian Foundation for Innovation (CFI), Natural Science and Engineering Council of Canada (NSERC), the National Alliance for Research on Schizophrenia and Depression USA (NARSAD), the Stanley Medical Research Institute USA (SMRI), the Parkinson Society of Canada (PSC), the US Parkinson’s Disease Foundation (PDF) and the Michael J. Fox Foundation for Parkinson’s disease (MJFF).

Dr. Daniel Lévesque Grants